Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors

Details for Australian Patent Application No. 2005276135 (hide)

Owner Pfizer Inc.

Inventors Cui, Jingrong Jean; Pairish, Mason Alan; Jia, Lei; Meng, Jerry Jialun; TranDube, Michelle Bich; Funk, Lee Andrew; Shen-Hong; Nambu, Mitchell, David; Kung, Pei-Pei

Agent Allens Arthur Robinson

Pub. Number AU-B-2005276135

PCT Pub. Number WO2006/021884

Priority 60/605,086 26.08.04 US

Filing date 15 August 2005

Wipo publication date 2 March 2006

Acceptance publication date 28 April 2011

International Classifications

C07D 241/20 (2006.01) Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 403/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

Event Publications

1 February 2007 PCT application entered the National Phase

  PCT publication WO2006/021884 Priority application(s): WO2006/021884

28 April 2011 Application Accepted

  Published as AU-B-2005276135

25 August 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005276136-Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates

2005276132-Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors